Corporate Profile Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financial Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Investor Resources Investor FAQs Investor Email Alerts Contact IR Year None202120202019 Nov 12, 2021 Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175 Nov 10, 2021 Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update Nov 04, 2021 Ikena Oncology to Participate in November 2021 Virtual Investor Conferences Nov 02, 2021 Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930 Oct 07, 2021 Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment Oct 01, 2021 Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Sep 02, 2021 Ikena Oncology to Participate in September 2021 Virtual Investor Conferences Aug 12, 2021 Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs Jul 08, 2021 Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 May 26, 2021 Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds
Year None202120202019 Nov 12, 2021 Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175 Nov 10, 2021 Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update Nov 04, 2021 Ikena Oncology to Participate in November 2021 Virtual Investor Conferences Nov 02, 2021 Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930 Oct 07, 2021 Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment Oct 01, 2021 Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Sep 02, 2021 Ikena Oncology to Participate in September 2021 Virtual Investor Conferences Aug 12, 2021 Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs Jul 08, 2021 Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 May 26, 2021 Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference Current page 1 Page 2 Next page next › Last page last »
Nov 12, 2021 Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175
Nov 02, 2021 Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
Oct 07, 2021 Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Oct 01, 2021 Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Aug 12, 2021 Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs
Jul 08, 2021 Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021
